1. Home
  2. TRVI vs ADSE Comparison

TRVI vs ADSE Comparison

Compare TRVI & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • ADSE
  • Stock Information
  • Founded
  • TRVI 2011
  • ADSE 1980
  • Country
  • TRVI United States
  • ADSE Ireland
  • Employees
  • TRVI N/A
  • ADSE N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • ADSE Industrial Specialties
  • Sector
  • TRVI Health Care
  • ADSE Consumer Discretionary
  • Exchange
  • TRVI Nasdaq
  • ADSE Nasdaq
  • Market Cap
  • TRVI 725.7M
  • ADSE 581.6M
  • IPO Year
  • TRVI 2019
  • ADSE N/A
  • Fundamental
  • Price
  • TRVI $7.01
  • ADSE $9.94
  • Analyst Decision
  • TRVI Strong Buy
  • ADSE
  • Analyst Count
  • TRVI 10
  • ADSE 0
  • Target Price
  • TRVI $19.35
  • ADSE N/A
  • AVG Volume (30 Days)
  • TRVI 2.0M
  • ADSE 63.5K
  • Earning Date
  • TRVI 11-05-2025
  • ADSE 09-12-2025
  • Dividend Yield
  • TRVI N/A
  • ADSE N/A
  • EPS Growth
  • TRVI N/A
  • ADSE N/A
  • EPS
  • TRVI N/A
  • ADSE N/A
  • Revenue
  • TRVI N/A
  • ADSE $113,896,884.00
  • Revenue This Year
  • TRVI N/A
  • ADSE $219.58
  • Revenue Next Year
  • TRVI N/A
  • ADSE N/A
  • P/E Ratio
  • TRVI N/A
  • ADSE N/A
  • Revenue Growth
  • TRVI N/A
  • ADSE 2.45
  • 52 Week Low
  • TRVI $2.36
  • ADSE $9.00
  • 52 Week High
  • TRVI $8.78
  • ADSE $16.35
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 44.05
  • ADSE 33.77
  • Support Level
  • TRVI $7.09
  • ADSE $11.76
  • Resistance Level
  • TRVI $8.78
  • ADSE $13.25
  • Average True Range (ATR)
  • TRVI 0.43
  • ADSE 0.80
  • MACD
  • TRVI -0.07
  • ADSE -0.22
  • Stochastic Oscillator
  • TRVI 4.32
  • ADSE 3.64

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About ADSE ADS-TEC ENERGY PLC

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.

Share on Social Networks: